# Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

> **NCT01693601** · PHASE1,PHASE2 · COMPLETED · sponsor: **John Mascarenhas** · enrollment: 15 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01693601
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2018-05-18
- **Final completion:** 2018-05-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693601, "Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01693601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*